Glucose Sensor After Hospital Discharge for People With Type 2 or Steroid-Induced Diabetes
Tests a wearable glucose sensor in adults with diabetes going home on insulin.
Key facts
- Who runs it
- Icahn School of Medicine at Mount Sinai
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- CGM After Discharge From Hospital
- Status
- Not yet recruiting
- People taking part
- 64 people, planned
- Started
- 30 Sept 2026
- Expected to end
- Nov 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Libre 3 Plus continuous glucose monitoring (CGM) system
- Blinded Continuous Glucose Monitoring
- Finger stick
- Record updated
- 10 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 or steroid-induced diabetes who were treated in hospital and will use insulin after discharge. It compares two ways of monitoring blood sugar.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Type 2 diabetes or steroid-induced diabetes, treated in hospital, with a plan for insulin use after discharge
- Earlier treatment
- Inpatient treatment for type 2 or steroid-induced diabetes during the hospital stay
Main reasons for not taking part
- Type 1 diabetes
- Plan to be discharged to a rehabilitation, skilled nursing or hospice facility
- Contra-indication to sensor placement
- Pregnancy
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adult 18 years or older
- Inpatient treatment for type 2 or steroid induced diabetes during hospitalization, with plan for insulin use after discharge
Who cannot take part
- Type 1 diabetes
- Plan for discharge to rehabilitation/skilled nursing/hospice facility
- Contra-indication to sensor placement
- Pregnancy
Where in United States
- Icahn School of Medicine at Mount SinaiNew York, United StatesContact: Grenye O'Malley, MDNot yet recruiting
About the trial
What the trial wants to find out
This is an investigator initiated prospective, randomized controlled trial which aims to compare two groups of patients with either type 2 or steroid-induced diabetes who are discharged with insulin. The intervention group will use the Libre 3 Plus continuous glucose monitoring (CGM) system at discharge, while the control group will use blinded CGM and fingerstick monitoring. Both the intervention and control groups will wear the sensor for 28 days post discharge and participate in telehealth diabetes management visits. The target enrollment for the study is 65 participants and participants are expected to be in the study for up to 35 days.
The 2 groups in the trial
- Libre 3 Plus continuous glucose monitoring (CGM) systemTreatment being tested
use of unmasked continuous glucose monitoring
- Blinded CGM and fingerstick monitoringExisting treatment, for comparison
Self-monitoring blood glucose (SMBG)+masked CGM
Treatment: Blinded Continuous Glucose Monitoring and Finger stick
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Continuous Glucose Monitoring for Post-discharge Diabetes Management
- Plain-language title
- Glucose Sensor After Hospital Discharge for People With Type 2 or Steroid-Induced DiabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 August 2026